Top

Published in:

01-02-2020 | Myasthenia Gravis | Original article

Medication adherence in patients with myasthenia gravis in Brazil: a cross-sectional study

Authors: Bruno Kusznir Vitturi, Ada Pellegrinelli, Berenice Cataldo Oliveira Valerio

Published in: Acta Neurologica Belgica | Issue 1/2020

Abstract

Advances in the treatment of MG have allowed most patients to effectively treat their disorder with oral medications. In parallel, non-adherence to medication treatment regimens is a worldwide health problem. Other chronic neurological disorders have already been associated with low adherence to treatment. However, the literature regarding adherence among patients with MG is definitely poor. The purpose of this study was to capture the prevalence and the associated factors of non-adherence to pharmacological treatment in patients with MG. We carried out a cross-sectional cohort study with 58 consecutive patients with MG from a university-affiliated referral hospital in São Paulo, Brazil. We registered clinical and sociodemographic data and patients were classified according to the MGFA classification. Clinical severity was assessed with myasthenia gravis composite (MGC) scale. Neuropsychiatric symptoms were evaluated with the Hospital Anxiety and Depression Scale (HADS) and quality of life with the 15-Item Quality Of Life Instrument for myasthenia gravis scale (MG-QOL15). Adherence to pharmacological treatment was evaluated using the 8-item Morisky Medication Adherence Scale (MMAS-8). There were 26 (44.8%) patients adherent to treatment. Low adherence was associated with poor educational attainment, longer time of disease and greater daily number of pills (p < 0.05). Patients with poor compliance to treatment presented worse quality of life and increased neuropsychiatric symptoms (p < 0.05). Adherence can be relatively challenging in patients with MG. Medical approach should recognize that therapeutic success in the treatment of MG goes through adherence to treatment.

Jayam Trouth A, Dabi A, Solieman N, Kurukumbi M, Kalyanam J (2012) Myasthenia gravis: a review. Autoimmune Dis 2012:874680. https://doi.org/10.1155/2012/874680 CrossRefPubMedPubMedCentral

Gilhus NE, Verschuuren JJ (2015) Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 14(10):1023–1036. https://doi.org/10.1016/S1474-4422(15)00145-3 CrossRefPubMed

Richman DP, Agius MA (2003) Treatment of autoimmune myasthenia gravis. Neurology 61(12):1652–1661. https://doi.org/10.1212/01.WNL.0000098887.24618.A0 CrossRefPubMed

Sussman J, Farrugia ME, Maddison P, Hill M, Leite MI, Hilton-Jones D (2015) Myasthenia gravis: association of British neurologists’ management guidelines. Pract Neurol 15(3):199–206. https://doi.org/10.1136/practneurol-2015-001126 CrossRefPubMed

Behin A, Le Panse R (2018) New pathways and therapeutic targets in autoimmune myasthenia gravis. J Neuromuscul Dis 5(3):265–277. https://doi.org/10.3233/JND-170294 CrossRefPubMedPubMedCentral

Osterberg L, Blaschke T (2005) Drug therapy: adherence to medication. N Engl J Med 353(5):487–497. https://doi.org/10.1056/NEJMra050100 CrossRefPubMed

Valldeoriola F, Coronell C, Pont C et al (2011) Socio-demographic and clinical factors influencing the adherence to treatment in Parkinson’s disease: the ADHESON study. Eur J Neurol 18(7):980–987. https://doi.org/10.1111/j.1468-1331.2010.03320.x CrossRefPubMed

de Ernst L, Harden CL, Pennel PB et al (2016) Medication adherence in women with epilepsy who are planning pregnancy. Epilepsia 57(12):2039–2044. https://doi.org/10.1111/epi.13586 CrossRefPubMedPubMedCentral

Idiáquez JF, González S, Lasso-Peñafiel J, Barnett C (2018) Adhesión al tratamiento farmacológico y descripción de sus factores asociados en pacientes con miastenia grave. Rev Neurol 66:15–20PubMed

10.

Jaretzki A, Barohn RJ, Ernstoff RM et al (2000) Myasthenia gravis: recommendations for clinical research standards. Ann Thorac Surg 70(1):327–334. https://doi.org/10.1212/WNL.55.1.16 CrossRefPubMed

11.

Burns TM, Conaway M, Sanders DB (2010) The MG composite: a valid and reliable outcome measure for myasthenia gravis. Neurology 74(18):1434–1440. https://doi.org/10.1212/WNL.0b013e3181dc1b1e CrossRefPubMedPubMedCentral

12.

Burns TM, Grouse CK, Wolfe GI, Conaway MR, Sanders DB (2011) The MG-QOL15 for following the health-related quality of life of patients with myasthenia gravis. Muscle Nerve 43(1):14–18. https://doi.org/10.1002/mus.21883 CrossRefPubMed

13.

Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67(6):361–370. https://doi.org/10.1111/j.1600-0447.1983.tb09716.x CrossRefPubMed

14.

de Oliveira-Filho AD, Morisky DE, Neves SJF, Costa FA, De Lyra DP (2014) The 8-item Morisky Medication Adherence Scale: validation of a Brazilian–Portuguese version in hypertensive adults. Res Soc Adm Pharm 10(3):554–561. https://doi.org/10.1016/j.sapharm.2013.10.006 CrossRef

15.

Brown MT, Bussell JK (2011) Medication adherence: WHO cares? Mayo Clin Proc 86(4):304–314. https://doi.org/10.4065/mcp.2010.0575 CrossRefPubMedPubMedCentral

16.

Ferrari CMM, De Sousa RMC, Castro LHM (2013) Factors associated with treatment non-adherence in patients with epilepsy in Brazil. Seizure 22(5):384–389. https://doi.org/10.1016/j.seizure.2013.02.006 CrossRefPubMed

17.

Santos-García D, Prieto-Formoso M, De La Fuente-Fernández R (2012) Levodopa dosage determines adherence to long-acting dopamine agonists in Parkinson’s disease. J Neurol Sci 318(1–2):90–93. https://doi.org/10.1016/j.jns.2012.03.018 CrossRefPubMed

18.

Alkatheri A, Albekairy A (2013) Does the patients’ educational level and previous counseling affect their medication knowledge? Ann Thorac Med 8(2):105–108. https://doi.org/10.4103/1817-1737.109823 CrossRefPubMedPubMedCentral

19.

Fleisher J, Bhatia R, Margus C, Pruitt A, Dahodwala N (2014) Health literacy and medication awareness in outpatient neurology. Neurol Clin Pract 4(1):71–81. https://doi.org/10.1212/01.CPJ.0000436211.73013.ab CrossRefPubMedPubMedCentral

20.

Nieuwlaat R, Wilczynski N, Navarro T et al (2014) Interventions for enhancing medication adherence. Cochrane Database Syst Ver 11:CD000011. https://doi.org/10.1002/14651858.cd000011.pub4 CrossRef

21.

Praska JL, Kripalani S, Seright AL, Jacobson TA (2005) Identifying and assisting low-literacy patients with medication use: a survey of community pharmacies. Ann Pharmacother 39(9):1441–1445. https://doi.org/10.1345/aph.1G094 CrossRefPubMed

22.

Bangalore S, Kamalakkannan G, Parkar S, Messerli FH (2007) Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 120(8):713–719. https://doi.org/10.1016/j.amjmed.2006.08.033 CrossRefPubMed

23.

Claxton AJ, Cramer J, Pierce C (2001) A systematic review of the associations between dose regimens and medication compliance. Clin Ther 23(8):1296–1310. https://doi.org/10.1016/S0149-2918(01)80109-0 CrossRefPubMed

24.

Balu S, Simko RJ, Quimbo RM, Cziraky MJ (2009) Impact of fixed-dose and multi-pill combination dyslipidemia therapies on medication adherence and the economic burden of sub-optimal adherence. Curr Med Res Opin 25(11):2765–2775. https://doi.org/10.1185/03007990903297741 CrossRefPubMed

25.

Chapman RH, Benner JS, Petrilla AA et al (2005) Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 165(10):1147–1152. https://doi.org/10.1001/archinte.165.10.1147 CrossRefPubMed

26.

Varma A, Zis P (2019) Nocebo effect in myasthenia gravis: systematic review and meta-analysis of placebo-controlled clinical trials. Acta Neurol Belg 119(2):257–264. https://doi.org/10.1007/s13760-019-01143-1 CrossRefPubMed

27.

Kulaksizoglu IB (2007) Mood and anxiety disorders in patients with myasthenia gravis: aetiology, diagnosis and treatment. CNS Drugs 21(6):473–481. https://doi.org/10.2165/00023210-200721060-00004 CrossRefPubMed

28.

Ybarra MI, Kummer A, Frota ERC, de Oliveira JT, Gomez RS, Teixeira AL (2011) Psychiatric disorders in myasthenia gravis. Arq Neuropsiquiatr 69(2A):176–179. https://doi.org/10.1590/s0004-282x2011000200006 CrossRefPubMed

29.

Kronish IM, Rieckmann N, Halm EA et al (2006) Persistent depression affects adherence to secondary prevention behaviors after acute coronary syndromes. J Gen Intern Med 21(11):1178–1183. https://doi.org/10.1111/j.1525-1497.2006.00586.x CrossRefPubMedPubMedCentral

30.

Scalzo P, Kummer A, Cardoso F, Teixeira AL (2009) Depressive symptoms and perception of quality of life in Parkinson’s disease. Arq Neuropsiquiatr 67(2A):203–208. https://doi.org/10.1590/s0004-282x2009000200006 CrossRefPubMed

31.

Misra UK, Kalita J, Singh VK, Kumar S (2019) A study of comorbidities in myasthenia gravis. Acta Neurol Belg. https://doi.org/10.1007/s13760-019-01102-w CrossRefPubMedPubMedCentral

32.

DiMatteo MR, Lepper HS, Croghan TW (2000) Depression is a risk factor for noncompliance with medical treatment. Arch Intern Med 160(14):2101–2107. https://doi.org/10.1001/archinte.160.14.2101 CrossRefPubMed

33.

De Lapiscina EHM, Aguirre MEE, Blanco TA, Pascual IJ (2012) Myasthenia gravis: sleep quality, quality of life, and disease severity. Muscle Nerve 46(2):174–180. https://doi.org/10.1002/mus.23296 CrossRef

34.

Raggi A, Leonardi M, Antozzi C et al (2010) Concordance between severity of disease, disability and health-related quality of life in myasthenia gravis. Neurol Sci 31(1):41–45. https://doi.org/10.1007/s10072-009-0167-y CrossRefPubMed

35.

Mourão A, Gomez R, Barbosa L et al (2016) Determinants of quality of life in Brazilian patients with myasthenia gravis. Clinics 71(7):370–374. https://doi.org/10.6061/clinics/2016(07)03 CrossRefPubMedPubMedCentral

36.

Straka I, Minár M, Gažová A, Valkovič P, Kyselovič J (2018) Clinical aspects of adherence to pharmacotherapy in Parkinson disease: a PRISMA-compliant systematic review. Medicine (United States). 97(23):e10962. https://doi.org/10.1097/MD.0000000000010962 CrossRef

Title: Medication adherence in patients with myasthenia gravis in Brazil: a cross-sectional study
Authors: Bruno Kusznir Vitturi
Ada Pellegrinelli
Berenice Cataldo Oliveira Valerio
Publication date: 01-02-2020
Publisher: Springer International Publishing
Keyword: Myasthenia Gravis
Published in: Acta Neurologica Belgica / Issue 1/2020
Print ISSN: 0300-9009
Electronic ISSN: 2240-2993
DOI: https://doi.org/10.1007/s13760-019-01209-0

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Medication adherence in patients with myasthenia gravis in Brazil: a cross-sectional study

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2020

Neuro-images Kernohan–Woltman notch phenomenon in acute subdural hematoma

Evaluation of retinal alterations in Parkinson disease and tremor diseases

Revision surgery after instrumental fixation in patient with butterfly vertebra: a case report

A study of comorbidities in myasthenia gravis

MRI findings in fragile X-associated tremor/ataxia syndrome

Median nerve ultrasound in carpal tunnel syndrome with normal electrodiagnostic tests